"Greenwich LifeSciences Announces Poster Presentation of Five Year Data for GP2 Phase IIb Clinical Trial, Showing 0% Recurrence of Breast Cancer."
More from Stocks
These recently downgraded names are displaying both quantitative and technical deterioration.
Looking to eliminate company-specific risk? Here's how I'd play these two popular exchange-traded funds.
Selecting and buying the right shares produces big profits -- but only when the conditions are right.
Military contractors tend to have strong performance, even amid recessions. Here are three names that could provide steady income now.